Mydecine

Last updated
Mydecine
Industry Pharmaceutical; Psychedelic medicine
Founded2020;5 years ago (2020) in Denver, Colorado
Headquarters
Vancouver, British Columbia
,
Canada [1]
Website mydecine.com

Mydecine Innovations Group, or simply Mydecine, is an American and Canadian pharmaceutical company that is developing psychedelics and entactogens as medicines. [2] [3] [4]

Contents

In August 2022, it was reported that Mydecine was experiencing financial difficulties and might cease operations. [4] [5] However, the company was able to obtain more funding and did not shutdown. [4] Mydecine made the first legal import of magic mushrooms into Canada in 2021. [6] [7]

Mydecine's drug candidates include the psychedelics psilocybin (MYCO-001, MYCO-003), [8] [9] [10] MYCO-004 (a patch-delivered tryptamine), [11] [12] and MYCO-005 (a novel aza psilocin analogue with putatively better safety) [13] [14] [2] and the novel MDMA-like entactogens MYCO-002 (putatively safer), [15] [16] MYCO-006 (short-acting), [17] [18] [5] [3] and MYCO-007 (short-acting). [19] [20] [21] [1]

Although the chemical structures of most of its drug candidates have not been disclosed, Mydecine has patented 5-BZT-MDMA (MY100) and 6-BZT-MDMA (MY101) as short-acting MDMA analogues. [22] [23] [24]

See also

Related Research Articles

<span class="mw-page-title-main">Substituted methylenedioxyphenethylamine</span> Class of psychoactive drugs

The substituted methylenedioxyphenethylamines represent a diverse chemical class of compounds derived from phenethylamines. This category encompasses numerous psychoactive substances with entactogenic, psychedelic, and/or stimulant properties, in addition to entheogens. These compounds find application as research chemicals, designer drugs, and recreational substances.

<span class="mw-page-title-main">ITI-1549</span> Non-hallucinogenic 5-HT2A agonist

ITI-1549 is a putatively non-hallucinogenic serotonin 5-HT2A receptor agonist which is under development for the treatment of mood disorders and other psychiatric disorders. In addition to acting at the serotonin 5-HT2A receptor, it is also an antagonist of the serotonin 5-HT2B receptor and an agonist of the serotonin 5-HT2C receptor. The drug's route of administration has not been specified.

CYB003, or CYB-003, also known as deuterated psilocybin analogue, is a serotonergic psychedelic related to psilocybin which is under development for the treatment of major depressive disorder, alcoholism, and other psychiatric disorders. It is taken by mouth.

MSP-1014 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder, other depressive disorders, and anxiety disorders.

BMB-202 is a serotonin 5-HT2A receptor agonist and psychedelic hallucinogen which is under development for the treatment of depressive disorders and post-traumatic stress disorder (PTSD). It is taken by mouth. However, BMB-202 has also been evaluated by injection in preclinical studies.

LPH-48 is a selective serotonin 5-HT2A receptor agonist and psychedelic hallucinogen which is under development for the treatment of alcoholism. Its route of administration has not been specified.

MYCO-005 is a serotonin 5-HT2A receptor agonist and psychedelic hallucinogen which is under development for the treatment of depressive disorders and anxiety disorders.

α-Methylisotryptamine Monoaminergic drug

α-Methylisotryptamine is a synthetic compound belonging to the tryptamine class, known for its psychoactive properties. As a structural analog of α-methyltryptamine (αMT), isoAMT exhibits entactogenic and psychedelic effects.

Tactogen is a public benefit corporation and start-up pharmaceutical company based in Palo Alto, California that is developing novel MDMA-like entactogens and psychedelics as medicines. Its stated goal is to develop new MDMA-like drugs with improved effectiveness, tolerability, and safety, as well as gentleness and accessibility, for treatment of psychiatric disorders and other conditions. Tactogen was co-founded by neuroscientist Matthew J. Baggott and Luke Pustejovsky in 2020. Baggott is the chief executive officer (CEO) while Pustejovsky is the chief operating officer (COO).

MYCO-002 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders. It is said to be being developed towards the aim of improving the safety profile of MDMA. The drug is under development by Mydecine. It was patented in July 2021 and received breakthrough therapy designation from the Food and Drug Administration (FDA) in November 2021. As of November 2021, MYCO-002 is in the preclinical research for treatment of psychiatric disorders. The chemical structure of MYCO-002 does not yet appear to have been disclosed.

MYCO-006 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders. It is a short-acting and fast-onset MDMA analogue. Based on animal studies, it is predicted that MYCO-006 will have a duration of 1 to 2 hours, about one-third the 6- to 8-hour duration of MDMA, and to onset 4 times as fast as MDMA. MYCO-006 is being developed by Mydecine. As of February 2024, it is in preclinical research. The chemical structure of MYCO-006 does not yet appear to have been disclosed. 5-BZT-MDMA (MY100) and 6-BZT-MDMA (MY101) were described in Mydecine's patent for short-acting MDMA analogues.

MYCO-007 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders. It is a short-acting MDMA analogue. MYCO-007 is being developed by Mydecine. As of February 2024, it is in preclinical research. The chemical structure of MYCO-007 does not yet appear to have been disclosed. 5-BZT-MDMA (MY100) and 6-BZT-MDMA (MY101) were described in Mydecine's patent for short-acting MDMA analogues

MYCO-004 is a patch-delivered psychedelic tryptamine which is under development for the treatment of psychiatric disorders. It is anticipated to allow for precision dosing and to have a short duration of approximately 2 hours. The drug is being developed by Mydecine. As of December 2021, it is in preclinical research for psychiatric disorders. The exact chemical structure of MYCO-004 does not yet seem to have been disclosed.

Cybin IRL is a Canadian pharmaceutical company that is developing psychedelic drugs as medicines.

DLX-159 is a putatively non-hallucinogenic psychoplastogen which is under development for the treatment of major depressive disorder and other psychiatric disorders. It is taken by mouth.

References

  1. 1 2 Simonelli, Gary (10 April 2023). "The Use of AI Technology is Increasing the Potential of Mydecine Innovations Group to Successfully Commercialize Psychedelic Drug Candidates". CEOCFO. Retrieved 29 January 2025.
  2. 1 2 Koning E, Solmi M, Brietzke E (August 2024). "The Influence of Stakeholder Interests on Safety Outcome Reporting in Psychedelic Research and Implications for Science Communication". Trends Psychiatry Psychother. doi: 10.47626/2237-6089-2024-0866 . PMID   39088699. The company Mydecine Innovations Group developed a proprietary compound MYCO-005, which mimics the active ingredient in psilocybin, but with a more rapid onset and shorter duration of action.84 [...]
  3. 1 2 Dunne, Rowan (24 April 2023). "Mydecine's MDMA with rapid onset and a short duration shows promising results". Mugglehead Investment Magazine. Retrieved 29 January 2025.
  4. 1 2 3 "Mydecine Looks Set to Shutter; MindMed Gains 'Meme Stock' Status; atai 'Streamlilnes' Pipeline; California Decrim. Bill Gutted". Psychedelic Alpha. 19 August 2022. Retrieved 29 January 2025.
  5. 1 2 Borchardt, Debra (17 August 2022). "Psilocybin Company Mydecine Is Down To $300k In Cash". Green Market Report. Retrieved 29 January 2025. Just last month Mydecine announced it has successfully synthesized multiple short-acting MDMA analogs. This family of analogs had been specifically designed by experts at Mydecine to have a shorter half-life than traditional MDMA. The company has named this family of novel molecules MYCO-006 and applied for patent coverage with the World Intellectual Property Organization.
  6. ↑ Gnam, Jared (11 December 2020). "Mydecine to make first legal import of psilocybin mushrooms into Canada". Mugglehead Investment Magazine. Retrieved 29 January 2025.
  7. ↑ Lansdowne, Laura Elizabeth (19 February 2021). "Behind the World-First Export of Jamaican Psilocybin Mushrooms". Neuroscience from Technology Networks. Retrieved 29 January 2025.
  8. ↑ "Psilocybin - Mydecine Innovations Group - AdisInsight". adisinsight.springer.com.
  9. ↑ "Delving into the Latest Updates on MYCO-001 with Synapse". Synapse. 23 January 2025. Retrieved 29 January 2025.
  10. ↑ "Delving into the Latest Updates on MYCO-003 with Synapse". Synapse. 23 January 2025. Retrieved 29 January 2025.
  11. ↑ "MYCO 004 - AdisInsight". adisinsight.springer.com.
  12. ↑ "Delving into the Latest Updates on MYCO-004 with Synapse". synapse.patsnap.com.
  13. ↑ "Research programme: second generation psilocin analogs - Mydecine Innovations Group - AdisInsight". adisinsight.springer.com.
  14. ↑ "Delving into the Latest Updates on MYCO-005 with Synapse". Synapse. 1 November 2024. Retrieved 1 November 2024.
  15. ↑ "MYCO 002 - AdisInsight". adisinsight.springer.com.
  16. ↑ "Delving into the Latest Updates on MYCO-002 with Synapse". synapse.patsnap.com.
  17. ↑ "Research programme: short acting methylenedioxymethamphetamine analogs - Mydecine Innovations Group - AdisInsight". adisinsight.springer.com.
  18. ↑ "Delving into the Latest Updates on MYCO-006 with Synapse". synapse.patsnap.com.
  19. ↑ "Delving into the Latest Updates on MYCO-007 with Synapse". synapse.patsnap.com.
  20. ↑ "2309151616480990.pdf" (PDF). Retrieved 23 October 2024. MYCO - 006 and 007 represent families of molecules that are based on MDMA molecules. MYCO -006 and MYCO – 007 have been developed in order to reduce the overall acute experience time of Generation 1 MDMA by increasing the metabolism properties of the drug.
  21. ↑ Mydecine Innovations Group (19 July 2022). "Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs". GlobeNewswire News Room. Retrieved 23 October 2024. Mydecine [...] announced it has successfully synthesized multiple short-acting MDMA analogs. This family of analogs have been specifically designed by experts at Mydecine to have a shorter half life than traditional MDMA. The Company has named this family of novel molecules MYCO-006 and have applied for patent coverage with the World Intellectual Property Organization.
  22. ↑ Mydecine (5 January 2024). "Novel short-acting psychoactive compounds of the mdma class". Google Patents. Retrieved 23 October 2024.
  23. ↑ "1-(1,3-benzoxathiol-5-yl)-N-methylpropan-2-amine". PubChem. Retrieved 23 October 2024.
  24. ↑ "1-(1,3-benzoxathiol-5-yl)-N,N-dimethylpropan-2-amine". PubChem. Retrieved 23 October 2024.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.